Results 31 to 40 of about 2,631,955 (205)

Dysembryoplastic Neuroepithelial Tumor: A Benign but Complex Tumor of the Cerebral Cortex [PDF]

, 2022
Dysembryoplastic neuroepithelial tumor (DNET) is a distinct type of low-grade glioneuronal tumor. Clinically, DNET is highly associated with intractable epilepsy in young children and adolescents.
김세훈
core   +1 more source

Correlation between LRP1B Mutations and Tumor Mutation Burden in Gastric Cancer [PDF]

Computational and Mathematical Methods in Medicine, 2021
Background. It has been shown that low-density lipoprotein receptor-related protein 1B (LRP1B) mutations correlate with tumor mutation burden (TMB) and prognosis in patients with melanoma and non-small-cell lung cancer, while the relationship between LRP1B mutations and TMB in gastric cancer needs further study.
Sizhe Hu, Xiaokang Zhao, Feng Qian, Cancan Jin, Kaishun Hou   +4 more
openaire   +2 more sources

Association between Tumor Mutational Burden, Stromal CD8+ Tumor-Infiltrating Lymphocytes, and Clinical Factors in Cervical Cancers Treated with Radiotherapy

, 2023
Background: Tumor mutational burden (TMB) and stromal CD8-positive tumor-infiltrating lymphocytes (CD8+TILs) serve important roles in antitumor immune responses to radiotherapy.
Ken Ando, Hanguang Ruan, Tatsuya Ohno, Takahiro Oike, Hiro Sato   +4 more
core   +1 more source

Value of DNA Repair Gene and TP53 Co-mutation in Predicting Effect of Immunotherapy on Lung Adenocarcinoma

Zhongliu Fangzhi Yanjiu, 2021
Objective To explore the value of DNA repair genes (DRGs) in predicting the effect of immunotherapy on lung adenocarcinoma based on second-generation sequencing technology.
CHEN Guangying, MA Junxun, HU Yi
doaj   +1 more source

Tumor Mutational Burden in Histiocytic Neoplasms

Blood, 2021
Abstract Background Histiocytic disorders are rare hematologic neoplasms characterized by their high clinical heterogeneity. Evidence of constitutive activation of the mitogen-activated protein kinase (MAPK) pathway in a number of these disorders has led to the increasing use of BRAF- and MEK-inhibitors as ...
Aldo A. Acosta-Medina, Jithma P. Abeykoon, Surendra Dasari, Antonious Z. Hazim, N. Nora Bennani, Terra Lasho, Aishwarya Ravindran, Karen Rech, Mithun V. Shah, Gaurav Goyal, Ronald Go   +10 more
openaire   +1 more source

Effect of prior therapy on tumor mutational burden in NSCLC [PDF]

Translational Lung Cancer Research, 2021
Higher tumor mutation burden (TMB) in advanced non-small cell lung cancer (NSCLC) is associated with superior outcomes with checkpoint inhibitor therapy. Tissue samples subject to TMB analysis may be acquired after DNA-damaging therapies such as chemotherapy or radiation. The impact of these therapies on TMB results is unclear.
Jonna, Sushma, Vanderwalde, Ari, Nieva, Jorge, Poorman, Kelsey Anne, Saul, Michelle, von Buttlar, Xinyu, Hu, John Y., Liu, Stephen V.   +7 more
openaire   +2 more sources

SETD2 variation correlates with tumor mutational burden and MSI along with improved response to immunotherapy

BMC Cancer, 2023
Background SETD2 protects against genomic instability via maintenance of homologous recombination repair (HRR) and mismatch repair (MMR) in neoplastic cells.
Xiaobin Zheng, Jing Lin, Jiani Xiong, Yanfang Guan, Bin Lan, Yi Li, Xuan Gao, Zhaodong Fei, Lisha Chen, Lizhu Chen, Ling Chen, Gang Chen, Zengqing Guo, Xin Yi, Weiguo Cao, Xinghao Ai, Chengzhi Zhou, Xiaofeng Li, Jun Zhao, Xiangtao Yan, Qitao Yu, Lu Si, Yu Chen, Chuanben Chen   +23 more
doaj   +1 more source

DACH1 mutation frequency in endometrial cancer is associated with high tumor mutation burden.

PLoS ONE, 2020
ObjectiveDACH1 is a transcriptional repressor and tumor suppressor gene frequently mutated in melanoma, bladder, and prostate cancer. Loss of DACH1 expression is associated with poor prognostic features and reduced overall survival in uterine cancer.
McKayla J Riggs, Nan Lin, Chi Wang, Dava W Piecoro, Rachel W Miller, Oliver A Hampton, Mahadev Rao, Frederick R Ueland, Jill M Kolesar   +8 more
doaj   +1 more source

Advantages and Limitations of Monitoring Circulating Tumor DNA Levels to Predict the Prognosis of Patients Diagnosed With Gastric Cancer

Biomarker Insights, 2022
Next-generation sequencing-based genomic profiling facilitates biomarker detection by cell-free DNA (cfDNA) liquid biopsy. However, the efficiency of mutation calling and the prognostic value of cfDNA biomarkers are disputed.
Wan He, Jingxin Yang, Xiao Sun, Shunda Jiang, Jinchan Jiang, Ming Liu, Tianhao Mu, Yingmei Li, Xiaoni Zhang, Jingxian Duan, Ruilian Xu   +10 more
doaj   +1 more source

Methods of measurement for tumor mutational burden in tumor tissue

Translational Lung Cancer Research, 2018
Immunotherapies based on immune checkpoint inhibitors are emerging as an innovative treatment for different types of advanced cancers. While the utility of immune checkpoint inhibitors has been clearly demonstrated, the response rate is highly variable across individuals.
Melendez, Barbara, Van Campenhout, Claude, Rorive, Sandrine, Remmelink, Myriam, Salmon, Isabelle, D'Haene, Nicky   +5 more
openaire   +4 more sources